Dr. Jane L. Meisel, MD
Hospitalist (Hospitalist Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 168
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Harvard Medical School
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hospitalist Physician primary
MA license 242890
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Emory University Hospital Atlanta, GA
- Emory University Hospital Midtown Atlanta, GA
- Saint Joseph's Hospital of Atlanta, Inc Atlanta, GA
- Emory Decatur Hospital Decatur, GA
- Emory Johns Creek Hospital Johns Creek, GA
Medical groups
- The Emory Clinic Inc (3,568 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 168
- Services billed
- 314
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 112 | 94 |
| Established patient office or other outpatient visit, 30-39 minutes | 106 | 71 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 15 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Boston, MA | 150 |
| Ibrance (palbociclib) | 88 |
| Dexamethasone Other prescribers in Boston, MA | 86 |
| Tamoxifen Citrate Other prescribers in Boston, MA | 70 |
| Gabapentin Other prescribers in Boston, MA | 67 |
| Anastrozole Other prescribers in Boston, MA | 63 |
| Ondansetron Hcl Other prescribers in Boston, MA | 56 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 44 |
| Prochlorperazine Maleate Other prescribers in Boston, MA | 42 |
| Escitalopram Oxalate Other prescribers in Boston, MA | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $10,855 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $4,650 |
|---|---|
| Pfizer Inc. | $3,465 |
| AstraZeneca UK Limited | $2,740 |
| Consulting Fee | $10,855 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Sep 9, 2025 | Consulting Fee | $2,460 |
| AstraZeneca Pharmaceuticals LP Jan 16, 2025 | Consulting Fee | $1,370 |
| Pfizer Inc. Mar 11, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,260 |
| Pfizer Inc. Jun 13, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,260 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,028 |
| AstraZeneca UK Limited Apr 1, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,028 |
| Pfizer Inc. Jan 14, 2025 | Consulting Fee PAXLOVID · INFECTIOUS DISEASES | $945 |
| AstraZeneca Pharmaceuticals LP Oct 14, 2025 | Consulting Fee Truqap · Oncology | $820 |
| AstraZeneca UK Limited Jul 14, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $685 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $264,491 in research payments for these studies, mostly to the institutions running them.
- A randomized doubleblind phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2 breast cancer HER2CLIMB05
Pfizer Inc. - A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Jazz Pharmaceuticals Inc. - A single arm open label phase 2 study of tucatinib in combination with trastuzumab deruxtecan in subjects with previously treated unresectable locallyadvanced or metastatic HER2 breast cancer
Pfizer Inc. - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT01042379
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.